• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

In a nutshell...

S

sregan

Senior Member
Messages
703
Location
Southeast
After looking closely at a Methylation diagram it looks like just taking SAMe would get methylation going and that for those with the block that the SMP helps (Methionine synthase?) taking MCbl and MFolate will create more SAMe from recycled Homocysteine at the same time reducing a possibly harmful buildup of Homocysteine.

I was wondering also if those on the SMP might need to supplement with methyl donors if somehow there could be a deficiency once methylation gets started again?

Methylation-cycle.jpg
 
Lotus97

Lotus97

Senior Member
Messages
2,041
Location
United States
sregan
I think that might depend on a person's SNP. Rich recommends switching to methylcobalamin and raising methylfolate dosage if a person doesn't experience improvement with hydroxocobalamin and the starting dose of folinic acid and methylfolate. He's basing his recommendations on a study using an older version of his Simplified Methylation Protocol (SMP) in which SAMe and glutathione levels increased.
http://www.mecfs-vic.org.au/sites/w...Article-2009VanKonynenburg-TrtMethylStudy.pdf
index.php

index.php


The only study I could find using SAMe suggests SAMe doesn't raise or lower homocysteine. Perhaps taking SAMe in conjuction with a methylation protocol would produce different results
http://www.ncbi.nlm.nih.gov/pubmed/19422296?dopt=Abstract
Dietary supplement S-adenosyl-L-methionine (AdoMet) effects on plasma homocysteine levels in healthy human subjects: a double-blind, placebo-controlled, randomized clinical trial.
OBJECTIVES: To determine if exogenous S-adenosyl-l-methionine (AdoMet), a commonly used nutritional supplement, increases the level of plasma homocysteine (Hcy), a potential cardiovascular risk factor, in healthy human subjects.
DESIGN: Double-blind, placebo-controlled, randomized clinical trial.
SETTING: Mayo Clinic, Rochester, Minnesota.
SUBJECTS: Fifty-two (52) healthy human volunteers.
INTERVENTION: Subjects received placebo or AdoMet (800 mg per day) for 4 weeks. Hcy levels were measured before and after administration of AdoMet or placebo.
OUTCOME MEASURES: The primary outcome measure was change in Hcy level. Secondary outcome measures included an interim Hcy determination (at 2 weeks) and changes in levels of high-sensitivity C-reactive protein (hsCRP), lipids, and alanine aminotransferase.
RESULTS: There was no statistically significant change in Hcy between groups. Similarly, no statistically significant differences in change in Hcy or hsCRP levels were observed at 2 or 4 weeks. There was a small but statistically significant increase (p < 0.04) in alanine aminotransferase at week 2 and a statistically significant decrease (p < 0.04) in total cholesterol in the AdoMet group compared with the placebo group.
CONCLUSIONS: AdoMet at a daily dose of 800 mg for 4 weeks does not appear to significantly affect Hcy levels in the blood.
 
You must log in or register to reply here.